Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Rhea-AI Summary

Provectus Biopharmaceuticals announced non-clinical data on its rose bengal sodium (RBS) for treating full-thickness cutaneous wounds at the Society for Investigative Dermatology (SID) 2024 Annual Meeting. The study, led by Dr. Amina El Ayadi at the University of Texas Medical Branch, revealed that RBS treatment accelerated wound closure, reduced transepidermal water loss, increased collagen density, and improved vascularity with no toxicity or adverse effects. These findings suggest that RBS could enhance wound healing and prevent fibrosis, making it a promising treatment for severe skin wounds.

Positive

• Accelerated wound closure with significant difference observed at three days.
• Increased collagen density at seven and 14 days, aiding wound remodeling and tissue regeneration.
• Reduced transepidermal water loss by 14 days, indicating improved skin barrier function.
• No toxicity, mortality, organ abnormalities, or adverse effects observed at the highest tested dose.
• Increased vascularity between three and seven days, supporting wound closure.
• Reduced angiogenesis after wound closure, beneficial for preventing fibrosis.

Negative

• Erythema was increased at seven days, suggesting increased blood flow which may not always be beneficial.

• Accelerates wound closure and improves wound healing
  

KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas.

This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”).

A copy of UTMB’s poster presentation is available here: https://www.provectusbio.com/media/docs/publications/SID-2024_Poster-PV-10-2-42x44_inches-El_Ayadi.pdf.

The UTMB team and Dr. El Ayadi concluded that:

• The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed:
  • No toxicity or mortality,
  • No loss in body weight,
  • No organ abnormalities, and
  • No observed adverse effect level at the highest tested dose,
• Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function,
• Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing,
• Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure,
• RBS treatment:
  • Accelerated wound closure (significant difference at three days),
  • Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and
  • Reduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis.

About University of Texas Medical Branch at Galveston

Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture.

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of the Company’s:

• Annual Report on Form 10-K for the period ended December 31, 2023, and
  
• Quarterly Report on Form 10-Q for the period ended March 31, 2024.
  
  

#####

Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

FAQ

What did Provectus Biopharmaceuticals present at the SID 2024 Annual Meeting?

Provectus Biopharmaceuticals presented non-clinical data on the use of rose bengal sodium (RBS) for the treatment of full-thickness cutaneous wounds.

What were the key findings of the RBS study presented by Provectus Biopharmaceuticals at SID 2024?

The study found that RBS accelerated wound closure, improved skin barrier function, increased collagen density, and enhanced vascularity with no observed toxicity or adverse effects.

What is the significance of reduced transepidermal water loss in RBS treatment?

Reduced transepidermal water loss indicates improved skin barrier function, which is important for effective wound healing.

Were there any adverse effects observed in the RBS study presented by Provectus Biopharmaceuticals?

No, the study reported no toxicity, mortality, organ abnormalities, or adverse effects at the highest tested dose.

How did RBS treatment affect wound closure and collagen density?

RBS treatment accelerated wound closure and increased collagen density at seven and 14 days, supporting better wound remodeling and tissue regeneration.